MolMed S.p.A. Signs an Agreement With GlaxoSmithKline (GSK) to Develop a Production Process for a Gene Therapy
8/5/2011 11:02:55 AM
More...
|
MolMed S.p.A. Release: Results of three Phase II Trials in Lung Cancer Indications Confirm Safety and Antitumour Activity of NGR-hTNF
6/3/2011 8:10:53 AM
More...
|
FDA Grants Orphan Drug Designation for MolMed S.p.A.'s Investigational Antiumour Drug
8/29/2008 10:20:28 AM
More...
|
MolMed S.p.A. Key Preliminary Results of Phase II Trials Presented
5/30/2008 11:27:51 AM
More...
|
Immunicon Corporation (IMMC) And MolMed S.p.A. Enter Research And Laboratory Services Agreements
9/28/2006 12:12:01 PM
More...
|
Takara Bio And MolMed S.p.A. Announce That Phase I/II Clinical Trial Of HSV-TK Gene Therapy Delivers Positive Results
12/15/2005 6:16:33 PM
More...
|
Takara Bio , MolMed S.p.A. Conclude R&D Agreement For HIV Gene Therapy Treatment
10/19/2005 5:13:13 PM
More...
|
Takara Bio's Research Partner MolMed S.p.A., European Medicines Agency Begin Discussions Concerning Phase III Clinical Studies Of HSV-TK Gene Therapy
10/19/2005 5:12:16 PM
More...
|